Page 4 - Cardiovascular Risk Reduction News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events

— New Research Demonstrates Multifactorial Beneficial Effects of VASCEPA/VAZKEPA on Coronary Physiology and Plaque Progression — Data Further Advances Understanding of VASCEPA/VAZKEPA. | May 12, 2023

United arab emiratesUnited statesNew jerseyLoyola universityClin cardiolNabil abadirFarouc jafferLisa defrancescoMohamad kassabMarkg rabbatMark marmurColl cardiolDrug administrationCorporate communicationsHead of global medical affairsResearch demonstrates multifactorial beneficial

First Amended Complaint in Esperion Therapeutics, Inc v Daiichi Sankyo Europe GmbH, Case No 1:23-cv-02568-ER - Form 8-K

Case 1:23-cv-02568-ER Document 19 Filed 05/04/23 Page 1 of 37 Plaintiff Esperion Therapeutics, Inc. , by its attorneys, Gibson, Dunn &. | May 4, 2023

Ann arborUnited statesNew yorkRodney smithDaiichi sankyo europeBenoit creveauMatt benjaminPatricia vanstonPhilipp hoffmanBenjamin lookerStefan seyfriedEurope janJoanne foodyDaiichi sankyo europe gmbSheldon koenigDaiichi sankyo

Amarin Announces New REDUCE-IT® Data at ACC 23/WCC Showing

Post-Hoc Analysis Shows IPE Significantly Reduced Risk of First, Total Ischemic Events by 37% and 36% Respectively in Patients with Recent ACS Without.

United statesNew jerseyUnited kingdomUnited arab emiratesGreat britainClin cardiolAmerican heart associationDrug administrationExchange commissionAmarin corporationEuropean unionAmarin pharmaceuticals irelandJournal of the american college cardiologyA report from the american heart associationPost hoc analysis showsReduced risk

Amarin Corporation plc: Amarin Announces New REDUCE-IT® Data at ACC 23/WCC Showing Benefit of VASCEPA®/VAZKEPA® (Icosapent Ethyl) in High-Risk Patients with a Recent Acute Coronary Syndrome Event

Post-Hoc Analysis Shows IPE Significantly Reduced Risk of First, Total Ischemic Events by 37% and 36% Respectively in Patients with Recent ACS Without Increased Bleeding Analysis Builds on Consistently

United statesNew jerseyUnited kingdomUnited arab emiratesGreat britainClin cardiolColl cardiolAmerican heart associationDrug administrationExchange commissionAmarin corporationEuropean unionAmarin pharmaceuticals irelandJournal of the american college cardiologyA report from the american heart associationPost hoc analysis shows

Amarin Announces New REDUCE-IT® Data at ACC 23/WCC Showing Benefit of VASCEPA®/VAZKEPA® (Icosapent Ethyl) in High-Risk Patients with a Recent Acute Coronary Syndrome Event

Amarin Announces New REDUCE-IT® Data at ACC 23/WCC Showing Benefit of VASCEPA®/VAZKEPA® (Icosapent Ethyl) in High-Risk Patients with a Recent Acute Coronary Syndrome Event
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

United statesNew jerseyUnited kingdomUnited arab emiratesGreat britainClin cardiolAmerican heart associationDrug administrationExchange commissionAmarin corporationEuropean unionAmarin pharmaceuticals irelandJournal of the american college cardiologyA report from the american heart associationPost hoc analysis showsReduced risk